Company intelligence / Profile preview

D&D Securities

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Employees: ~24
Development stage: Other

Overview

D&D Pharmatech is advancing a portfolio of GLP-1 receptor agonist candidates with validated clinical efficacy. The company has multiple programs in Phase 2 clinical trials for neurodegenerative and metabolic diseases, with focus on oral and long-acting delivery technologies.

Therapeutic areas: EndocrinologyNeurologyInfectious DiseasesRheumatologyGastroenterologyPsychiatryOncology
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

Praxis Capital PartnersDS Asset ManagementKudos VenturesKorea Investment & Securities

Beyond the preview

Go deeper on D&D Securities.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D&D Securities.

Explore the full profile